-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
DexCom's Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$1.93 B | $2.45 B | $2.91 B | $3.62 B | $4.03 B |
| Cost of Revenue |
|
$646.60 M | $768.00 M | $1.03 B | $1.33 B | $1.59 B |
| Gross Profit |
|
$1.28 B | $1.68 B | $1.88 B | $2.29 B | $2.44 B |
| Research & Development |
|
$359.90 M | $604.20 M | $484.20 M | $505.80 M | $552.40 M |
| Selling,General & Administrative |
|
$620.70 M | $810.50 M | $1.00 B | $1.19 B | $1.29 B |
| Operating Expense |
|
$980.60 M | $1.41 B | $1.49 B | $1.69 B | $1.84 B |
| Operating Income |
|
$299.50 M | $265.80 M | $391.20 M | $597.70 M | $600.00 M |
| Net Income |
|
$493.60 M | $216.90 M | $341.20 M | $541.50 M | $576.20 M |
DexCom's Assets vs Liabilities & Equity
DexCom's Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$2.71 B | $2.73 B | $2.46 B | $2.72 B | $2.58 B |
| Inventories |
|
$234.70 M | $357.30 M | $306.70 M | $559.60 M | $542.60 M |
| Total Current Assets |
|
$3.42 B | $3.68 B | $3.67 B | $4.43 B | $4.30 B |
| Property,Plant and Equipment |
|
$608.60 M | $889.90 M | $1.14 B | $1.18 B | $1.40 B |
| Goodwill |
|
$19.30 M | $26.50 M | $25.70 M | $25.20 M | $22.80 M |
| Total Assets |
|
$4.29 B | $4.93 B | $5.39 B | $6.26 B | $6.48 B |
| Total Liabilities |
|
$2.46 B | $2.89 B | $3.26 B | $4.20 B | $4.38 B |
| Retained Earnings |
|
-$202.10 M | $138.70 M | $479.90 M | $1.02 B | $1.60 B |
| Total Shareholder Equity |
|
$1.83 B | $2.04 B | $2.13 B | $2.07 B | $2.10 B |
| Common Stock |
|
$100.00 K | $400.00 K | $400.00 K | $400.00 K | $400.00 K |
DexCom's Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$67.10 M | $102.00 M | $155.90 M | $186.00 M | $217.70 M |
| Dividends Payout |
|
- | - | - | - | - |
| Capital Expenditures (Capex) |
|
-$199.00 M | -$389.20 M | -$364.80 M | -$236.60 M | -$358.80 M |
| Free Cash Flow (FCF) |
|
$276.60 M | $53.30 M | $304.70 M | $511.90 M | $630.70 M |
DexCom's Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$1.28 B | $1.68 B | $1.88 B | $2.29 B | $2.44 B |
| Gross Profit Margin (%) |
|
66.44% | 68.63% | 64.72% | 63.19% | 60.46% |
| Operating Income |
|
$299.50 M | $265.80 M | $391.20 M | $597.70 M | $600.00 M |
| Operating Income Margin (%) |
|
15.54% | 10.86% | 13.44% | 16.50% | 14.88% |
| Net Income |
|
$493.60 M | $216.90 M | $341.20 M | $541.50 M | $576.20 M |
| Net Income Margin (%) |
|
25.62% | 8.86% | 11.73% | 14.95% | 14.29% |
| EBITDA |
|
$376.80 M | $377.50 M | $565.30 M | $916.70 M | $945.70 M |
| EBITDA Margin (%) |
|
19.56% | 15.42% | 19.43% | 25.31% | 23.45% |
DexCom's Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
27.02% | 10.62% | 16.01% | 26.18% | 27.40% |
| Return on Assets (ROA) |
|
11.50% | 4.40% | 6.33% | 8.64% | 8.89% |
| Debt to Equity |
|
100.71% | 105.67% | 100.62% | 125.40% | 123.06% |
| Debt to total asset |
|
42.87% | 43.74% | 39.78% | 41.41% | 39.90% |
| Enterprise value to revenue |
|
18.65 | 21.66 | 15.67 | 13.78 | 8.29 |
| Enterprise value to EBITDA |
|
95.34 | 140.51 | 80.66 | 54.46 | 35.37 |
| Enterprise value |
|
$35.92 B | $53.04 B | $45.60 B | $49.93 B | $33.45 B |
| Tax Rate (%) |
|
-119.38% | 15.54% | 12.69% | 23.78% | 18.73% |
Frequently Asked Questions
